AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32314974 — intervention group
Group type: EXPERIMENTAL
Intervention: The Box 2.0 intervention consisting of seven home measurement devices and a video consultation 2 weeks after discharge.
Number of subjects: 730
Study 32314974 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiac care for 3 months.
Number of subjects: 730
Study 32314974 — intervention group
Group type: EXPERIMENTAL
Intervention: The Box 2.0 intervention.
Number of subjects: 730
Study 32315306 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk components analysis using correlation, PCA, and graphical discovery analysis
Number of subjects: 156
Study 32315373 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-3L score at 1 week post-trauma
Number of subjects: 4883
Study 32315373 — intervention group
Group type: EXPERIMENTAL
Intervention: HUI2 score at 1 week post-trauma
Number of subjects: 4883
Study 32315373 — intervention group
Group type: EXPERIMENTAL
Intervention: HUI3 score at 1 week post-trauma
Number of subjects: 4883
Study 32315373 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-3L score at 24 months post-trauma
Number of subjects: 4883
Study 32315373 — intervention group
Group type: EXPERIMENTAL
Intervention: HUI2 score at 24 months post-trauma
Number of subjects: 4883
Study 32315373 — intervention group
Group type: EXPERIMENTAL
Intervention: HUI3 score at 24 months post-trauma
Number of subjects: 4883
Study 32315373 — intervention group
Group type: EXPERIMENTAL
Intervention: IES score at 1 week post-trauma
Number of subjects: 4883
Study 32315373 — intervention group
Group type: EXPERIMENTAL
Intervention: HADSA score at 1 week post-trauma
Number of subjects: 4883
Study 32315373 — intervention group
Group type: EXPERIMENTAL
Intervention: HADSD score at 1 week post-trauma
Number of subjects: 4883
Study 32315373 — intervention group
Group type: EXPERIMENTAL
Intervention: IES score at 24 months post-trauma
Number of subjects: 4883
Study 32315373 — intervention group
Group type: EXPERIMENTAL
Intervention: HADSA score at 24 months post-trauma
Number of subjects: 4883
Study 32315373 — intervention group
Group type: EXPERIMENTAL
Intervention: HADSD score at 24 months post-trauma
Number of subjects: 4883
Study 32315434 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser interstitial thermal therapy (LITT) using Robotic NeuroBlate System
Number of subjects: 223
Study 32316080 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (28-mg, 56-mg, or 84-mg) plus new oral antidepressant (OAD) administered twice a week for 4 weeks, followed by weekly or every-other-week for responders during a 48-week optimization/maintenance phase.
Number of subjects: 802
Study 32316080 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray plus new OAD
Number of subjects: 802
Study 32316799 — intervention group
Group type: EXPERIMENTAL
Intervention: High-altitude acclimatization
Number of subjects: 0
Study 32316976 — intervention group
Group type: EXPERIMENTAL
Intervention: SGRQ-I
Number of subjects: 150
Study 32316976 — intervention group
Group type: EXPERIMENTAL
Intervention: K-BILD
Number of subjects: 150
Study 32316977 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy with customized forces
Number of subjects: 11
Study 32316977 — intervention group
Group type: COMPARATOR
Intervention: Control group (trained without assistance)
Number of subjects: 11
Study 32317004 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C, Thiamine and Steroids
Number of subjects: 0
Study 32317004 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32318062 — intervention group
Group type: EXPERIMENTAL
Intervention: CCR4 targeting intervention, details on dosage and duration not available
Number of subjects: 0
Study 32318268 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose meropenem (2-g infusion over 3 h every 8 h)
Number of subjects: 78
Study 32318268 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose meropenem (1-g infusion over 3 h every 8 h)
Number of subjects: 78
Study 32318268 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose meropenem
Number of subjects: 78
Study 32318268 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose meropenem
Number of subjects: 78
Study 32318271 — intervention group
Group type: EXPERIMENTAL
Intervention: ThrIVe-B programme (psychological therapy)
Number of subjects: 12
Study 32318562 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraneural (invasive) sensory feedback
Number of subjects: 1
Study 32318562 — intervention group
Group type: COMPARATOR
Intervention: Electro-tactile (non-invasive) stimulation
Number of subjects: 1
Study 32318621 — intervention group
Group type: EXPERIMENTAL
Intervention: Blarcamesine (ANAVEX2-73), a selective sigma-1 receptor agonist, administered over a 57-week Phase 2a trial.
Number of subjects: 21
Study 32318621 — intervention group
Group type: EXPERIMENTAL
Intervention: Blarcamesine (ANAVEX2-73)
Number of subjects: 21
Study 32318641 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 981
Study 32318641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 981
Study 32318647 — intervention group
Group type: EXPERIMENTAL
Intervention: MLE4901 (NK3R antagonist)
Number of subjects: 28
Study 32318647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 32319040 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 300 mg twice daily on day 1 and then once daily for up to 28 days
Number of subjects: 65
Study 32319040 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 300 mg tablet
Number of subjects: 65
Study 32319144 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplements (DSs), average 9.12 (SD = 6.46) prescription drugs daily, 25 of 40 participants (62.5%) reported taking ≥1 DS daily.
Number of subjects: 40
Study 32319144 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (part of clinical trial), specific dosage and duration not mentioned.
Number of subjects: 40
Study 32319144 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (no control group mentioned).
Number of subjects: 40
Study 32319960 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioembolization with 90Y resin microspheres
Number of subjects: 1047
Study 32320048 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (10 mg/kg every 2 weeks for up to 2 years)
Number of subjects: 25
Study 32320798 — intervention group
Group type: EXPERIMENTAL
Intervention: Altis Single-Incision Sling System (SIS)
Number of subjects: 355
Study 32320798 — intervention group
Group type: COMPARATOR
Intervention: Standard midurethral transobturator and/or retropubic slings
Number of subjects: 355
Study 32320798 — intervention group
Group type: EXPERIMENTAL
Intervention: Altis SIS
Number of subjects: 355
Study 32320798 — intervention group
Group type: COMPARATOR
Intervention: Comparator group (standard slings)
Number of subjects: 355
Study 32320798 — intervention group
Group type: EXPERIMENTAL
Intervention: Altis SIS and standard slings
Number of subjects: 355
Study 32321635 — intervention group
Group type: EXPERIMENTAL
Intervention: Old and new antirheumatic drugs
Number of subjects: 0
Study 32322227 — intervention group
Group type: EXPERIMENTAL
Intervention: Child and Adolescent Dispositions Model
Number of subjects: 0
Study 32322227 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32322289 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (POMj) supplementation
Number of subjects: 9
Study 32322289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 32322662 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus
Number of subjects: 0
Study 32322662 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinia virus
Number of subjects: 0
Study 32322662 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes simplex virus
Number of subjects: 0
Study 32322662 — intervention group
Group type: EXPERIMENTAL
Intervention: Reovirus
Number of subjects: 0
Study 32322811 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) kits; 4 kits provided to peers/partners.
Number of subjects: 287
Study 32322811 — intervention group
Group type: COMPARATOR
Intervention: HIV Counseling and Testing (HCT) at local clinics; standard of care.
Number of subjects: 287
Study 32322811 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice of either clinic-based HCT or HIV self-testing (HIVST) kits; 4 HCT invitations provided to peers/partners.
Number of subjects: 287
Study 32323007 — intervention group
Group type: EXPERIMENTAL
Intervention: Strattice™ (PADM) placement
Number of subjects: 27
Study 32323174 — intervention group
Group type: EXPERIMENTAL
Intervention: College students
Number of subjects: 381
Study 32323174 — intervention group
Group type: EXPERIMENTAL
Intervention: Elementary school students
Number of subjects: 381
Study 32323174 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal education and mass media
Number of subjects: 381
Study 32323174 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet and family experience
Number of subjects: 381
Study 32323174 — intervention group
Group type: EXPERIMENTAL
Intervention: Family discussion
Number of subjects: 381
Study 32323217 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Psychoeducation (FPE) Fidelity Scale
Number of subjects: 5
Study 32323313 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional competence on PASS (Cognitively Mediated Instrumental Activities of Daily Living)
Number of subjects: 137
Study 32323313 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional competence on PASS
Number of subjects: 137
Study 32323313 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional competence on PASS combined with neurocognitive tests
Number of subjects: 137
Study 32324008 — intervention group
Group type: EXPERIMENTAL
Intervention: Sessions with less silence
Number of subjects: 21
Study 32324008 — intervention group
Group type: COMPARATOR
Intervention: Sessions with more silence
Number of subjects: 21
Study 32324916 — intervention group
Group type: EXPERIMENTAL
Intervention: Organised inpatient (stroke unit) care
Number of subjects: 5902
Study 32324916 — intervention group
Group type: COMPARATOR
Intervention: Stroke ward care
Number of subjects: 5902
Study 32324916 — intervention group
Group type: COMPARATOR
Intervention: Mobile stroke team care
Number of subjects: 5902
Study 32324916 — intervention group
Group type: COMPARATOR
Intervention: Mixed rehabilitation ward care
Number of subjects: 5902
Study 32324927 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa (3, 10, and 20 mg/kg every 2 weeks)
Number of subjects: 23
Study 32324981 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin 175 µg + Formoterol 20 µg
Number of subjects: 122
Study 32324981 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Formoterol 20 µg
Number of subjects: 122
Study 32324981 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin + Formoterol (combined administration)
Number of subjects: 122
Study 32324981 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol alone (evening administration)
Number of subjects: 122
Study 32325004 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Inspiratory Effort Assessment by Esophageal Manometry
Number of subjects: 0
Study 32325037 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-MERS-S vaccine
Number of subjects: 0
Study 32325043 — intervention group
Group type: EXPERIMENTAL
Intervention: NOACs (nonvitamin K antagonist oral anticoagulants)
Number of subjects: 6095
Study 32325043 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 6095
Study 32325043 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral anticoagulation only
Number of subjects: 6095
Study 32325043 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 6095
Study 32325043 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 6095
Study 32325043 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 6095
Study 32325043 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 6095
Study 32325043 — intervention group
Group type: COMPARATOR
Intervention: NOACs
Number of subjects: 6095
Study 32325171 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant (ASCT) followed by nonmyeloablative allogeneic stem cell transplant (alloSCT)
Number of subjects: 0
Study 32325171 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melphalan (200 mg/m2) for conditioning prior to ASCT
Number of subjects: 0
Study 32325220 — intervention group
Group type: EXPERIMENTAL
Intervention: SC-003 antibody Fab fragment
Number of subjects: 0
Study 32325220 — intervention group
Group type: COMPARATOR
Intervention: DPEP3
Number of subjects: 0
Study 32325432 — intervention group
Group type: EXPERIMENTAL
Intervention: Aeonose electronic nose
Number of subjects: 0
Study 32325461 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-Transplantation Cyclophosphamide (PTCy) and Ruxolitinib (45 mg from day-7 to day-2, 15 mg from day+5 to day+100)
Number of subjects: 20
Study 32325461 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-Transplantation Cyclophosphamide (PTCy) and Ruxolitinib
Number of subjects: 20
Study 32325480 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3050002 at 30 mg/kg/week
Number of subjects: 0
Study 32325480 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3050002 at 300 mg/kg/week
Number of subjects: 0
Study 32325480 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3050002 (both dosages)
Number of subjects: 0
Study 32325487 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fat ingestion
Number of subjects: 38
Study 32325487 — intervention group
Group type: COMPARATOR
Intervention: Lean control subjects
Number of subjects: 38
Study 32325849 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of the rs3749474 polymorphism of the CLOCK gene
Number of subjects: 898
Study 32325849 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary variables analyzed
Number of subjects: 898
Study 32326881 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid analysis (CSF)
Number of subjects: 372
Study 32327071 — intervention group
Group type: EXPERIMENTAL
Intervention: Early complications (≤30 days)
Number of subjects: 2811
Study 32327071 — intervention group
Group type: EXPERIMENTAL
Intervention: Early complications, pneumothorax, pocket hematoma
Number of subjects: 2811
Study 32327071 — intervention group
Group type: EXPERIMENTAL
Intervention: Device infection
Number of subjects: 2811
Study 32327071 — intervention group
Group type: EXPERIMENTAL
Intervention: All CIED-related complications
Number of subjects: 2811
Study 32327071 — intervention group
Group type: EXPERIMENTAL
Intervention: Early complications
Number of subjects: 2811
Study 32327102 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (n=7)
Number of subjects: 1020
Study 32327102 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment (n=29)
Number of subjects: 1020
Study 32327102 — intervention group
Group type: COMPARATOR
Intervention: Primary Aldosteronism (PA) patients
Number of subjects: 1020
Study 32327472 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-659, 60-120 mg, once-daily oral administration in 28-day cycles until disease progression or unacceptable toxicity
Number of subjects: 105
Study 32327479 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined anatomical imaging with CT and/or MR with positron emission tomography (PET) using a novel second-generation prostate-specific membrane antigen (PSMA) probe
Number of subjects: 75
Study 32327936 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Foot Health Promotion Programme (FHPP) for 4 weeks
Number of subjects: 37
Study 32328115 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 8 mg/kg per month (n=36)
Number of subjects: 90
Study 32328115 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 16 mg/kg per month (n=36)
Number of subjects: 90
Study 32328115 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=18)
Number of subjects: 90
Study 32328307 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum Arabic (GA) 30g/day for 12 weeks
Number of subjects: 40
Study 32328440 — intervention group
Group type: EXPERIMENTAL
Intervention: New in Town intervention
Number of subjects: 0
Study 32328500 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 0
Study 32328500 — intervention group
Group type: COMPARATOR
Intervention: VQ-SPECT
Number of subjects: 0
Study 32328660 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepotinib 215, 300 or 500 mg once daily
Number of subjects: 12
Study 32328660 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepotinib 500 mg once daily
Number of subjects: 12
Study 32328660 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepotinib
Number of subjects: 12
Study 32328893 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with gastroparetic symptoms
Number of subjects: 43
Study 32328953 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with linagliptin and metformin (500 mg)
Number of subjects: 1160
Study 32328953 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with linagliptin and metformin (1000 mg)
Number of subjects: 1160
Study 32328953 — intervention group
Group type: COMPARATOR
Intervention: Metformin alone (500 mg)
Number of subjects: 1160
Study 32328953 — intervention group
Group type: COMPARATOR
Intervention: Metformin alone (1000 mg)
Number of subjects: 1160
Study 32328953 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 1160
Study 32328976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib treatment
Number of subjects: 89
Study 32329093 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO treatment
Number of subjects: 18
Study 32329200 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdilatation with NC-balloons (diameter 3.6±0.6 mm, inflation pressure 19.3±2.0 atm)
Number of subjects: 32
Study 32329200 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdilatation with NC-balloons
Number of subjects: 32
Study 32329527 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide as add-on therapy
Number of subjects: 93
Study 32329658 — intervention group
Group type: EXPERIMENTAL
Intervention: Gore Viabahn Balloon-Expandable Endoprosthesis (VBX Stent-Graft)
Number of subjects: 134
Study 32330099 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy and intraventricular methotrexate
Number of subjects: 158
Study 32330099 — intervention group
Group type: COMPARATOR
Intervention: Local radiotherapy
Number of subjects: 158
Study 32330099 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 disease
Number of subjects: 158
Study 32330099 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 patients
Number of subjects: 158
Study 32330102 — intervention group
Group type: EXPERIMENTAL
Intervention: Omission of peg-filgrastim during dose-dense paclitaxel regimen
Number of subjects: 125
Study 32330231 — intervention group
Group type: EXPERIMENTAL
Intervention: Elvitegravir/cobicistat
Number of subjects: 14
Study 32330232 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-processed food (UPF) consumption categorized into quartiles (low, medium-low, medium-high, and high consumption)
Number of subjects: 886
Study 32330232 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher consumption of UPF (>3 servings/d)
Number of subjects: 886
Study 32330242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexidartinib (PLX3397) at doses of 800 to 5000 mg per day
Number of subjects: 90
Study 32330242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexidartinib (PLX3397) at doses of ≥2000 mg
Number of subjects: 90
Study 32330242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexidartinib (PLX3397) overall
Number of subjects: 90
Study 32330242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexidartinib (PLX3397) in dose expansion
Number of subjects: 90
Study 32330242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexidartinib (PLX3397) for responders with complete remission
Number of subjects: 90
Study 32330241 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA plus arsenic trioxide (ATO) plus gemtuzumab ozogamicin (GO)
Number of subjects: 70
Study 32330244 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (EPAG) administered at doses escalating from 50 to 300 mg/d.
Number of subjects: 34
Study 32330305 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 RNA detection in urine specimens
Number of subjects: 0
Study 32330305 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 RNA detection in blood specimens
Number of subjects: 0
Study 32330305 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 RNA detection in anal swabs
Number of subjects: 0
Study 32330305 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 RNA detection in oropharyngeal swabs
Number of subjects: 0
Study 32330510 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide modified release (MR), taken once daily for 14-18 weeks.
Number of subjects: 1244
Study 32330879 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective craniotomy
Number of subjects: 1452
Study 32331767 — intervention group
Group type: EXPERIMENTAL
Intervention: BRCA positive women after chemotherapy treatment
Number of subjects: 108
Study 32331767 — intervention group
Group type: EXPERIMENTAL
Intervention: BRCA negative women after chemotherapy treatment
Number of subjects: 108
Study 32331767 — intervention group
Group type: EXPERIMENTAL
Intervention: Untested/low risk controls after chemotherapy treatment
Number of subjects: 108
Study 32331767 — intervention group
Group type: COMPARATOR
Intervention: Before chemotherapy treatment AMH levels in BRCA positive and negative women
Number of subjects: 108
Study 32331936 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 40 mg (<50 kg) or 75 mg (≥50 kg) every 2 weeks (Q2W)
Number of subjects: 42
Study 32331936 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg (<50 kg) or 300 mg (≥50 kg) every 4 weeks (Q4W)
Number of subjects: 42
Study 32332141 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorised PowerSpiral Enteroscopy (PSE)
Number of subjects: 132
Study 32332461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 2 (with involuntary movements confirmed as possible TD)
Number of subjects: 739
Study 32332461 — intervention group
Group type: COMPARATOR
Intervention: Cohort 1 (without involuntary movements or with non-TD involuntary movements)
Number of subjects: 739